On Friday, Capricor Therapeutics (NASDAQ: CAPR) reported an update on its phase 2 trial known as ALLSTAR. It stated that the drug, CAP-1002 showed a low probability of achieving the primary endpoint of the study. The trial recruited a total of 142 patients who had suffered a heart attack with residual cardiac function. 

The patients were treated with the use of the company's stem cell treatment known as CAP-1002. The company stated that their treatment showed a low probability of being able to achieve statistical significance. The primary endpoint of the study was to assess a 12 month MRI that would possibly show a change in baseline after taking treatment with CAP-1002. 

More specifically, a change in size as a percent of the left ventricular mass of the heart measured by an MRI. The company will evaluate the full data set of this trial, but will focus more on its other trial. It is testing CAP-1002 in patients with Duchenne Muscular Dystrophy -- DMD. More specifically, it is looking at the skeletal muscle portion and cardiac portion of improvement in the disease. 

The trial is currently in a phase 1/2 trial known as the HOPE trial. It is treating young boys with DMD, and thus far have recruited up to 25 patients. Capricor has plans to move to recruit patients for a phase 2 trial that will be double-blind and placebo controlled. Pending regulatory approval this trial is expected to begin in the 2nd half of 2017.